Clinical Trials
Hypofractionated salvage radiation shows comparable early safety in phase III trial
Couñago et alClinical and Translational Radiation Oncology

A prespecified interim analysis of the prospective multicenter phase III URONCOR 06-24 trial evaluated early adverse events and patient-reported outcomes (PROs) among 250 patients receiving salvage radiotherapy (SRT) following radical prostatectomy. Patients received either moderate hypofractionation (n = 175) or conventional fractionation (n = 75; 66–70 Gy in 33–35 fractions). In the hypofractionated cohort, regimens included 62.5 Gy in 25 fractions (80.5%), 65.25 Gy in 29 fractions (7.5%), 60 Gy in 24 fractions (4.6%), and 52.5 Gy in 20 fractions (2.9%), reflecting an equivalent dose in 2-Gy fractions (EQD2) of approximately 65–71 Gy (α/β = 1.5).
Toxicity was evaluated using CTCAE v5.0, and PROs were assessed via EPIC-26 and EORTC QLQ-C30 instruments at baseline, 3 months, and 6 months. Pelvic nodal irradiation was administered significantly more often in the hypofractionation arm than in the conventional arm (39.4% vs 13.3%, p = 0.001). Over a median follow-up of 12.7 months, incidence of grade ≥2 genitourinary adverse events was 21.7% in the hypofractionation cohort versus 17.3% in the conventional fractionation cohort (p = 0.431). Grade ≥2 gastrointestinal toxicity rates were 10.8% and 4.0%, respectively (p = 0.079). PRO metrics demonstrated no clinically meaningful differences between the two treatment cohorts.
Multivariable modeling revealed that increasing patient age was linked to higher risk of grade ≥2 genitourinary toxicities, whereas receipt of pelvic nodal irradiation was associated with an elevated risk of grade ≥2 gastrointestinal toxicities. Study authors noted that because fractionation schedules were non-randomized, longer follow-up and adjustment for treatment-selection bias remain necessary before definitive comparative safety determinations can be made.
Key Takeaways
- At a median follow-up of 12.7 months, rates of grade ≥2 genitourinary adverse events were 21.7% with moderate hypofractionation versus 17.3% with conventional fractionation (p = 0.431), and grade ≥2 gastrointestinal adverse events occurred in 10.8% versus 4.0% (p = 0.079), with no clinically meaningful differences in patient-reported outcomes.
- On multivariable analysis, older age significantly correlated with an increased risk of grade ≥2 genitourinary toxicity, whereas pelvic nodal irradiation significantly correlated with an increased risk of grade ≥2 gastrointestinal toxicity.
Read the original sourceClinical and Translational Radiation Oncology
